New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab.

Published in: The Annals of pharmacotherapy (2020)

Targeted therapies with caplacizumab and ravulizumab are expected to reduce the burden of exacerbation, refractory disease, recurrence, and possibly death for thrombotic microangiopathy.

Keyphrases

chronic obstructive pulmonary disease
free survival
risk factors